SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025.

Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2025 financial and business results on Tuesday, May 6, 2025 at 4:30 p.m. ET. Following management’s prepared remarks and discussion of business results, the call will be open for questions.

A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at .

Participants may also pre-register any time before the call . Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

Following the live call, a replay will be available on the Company's Investor Relations website at . The webcast will be available on the Company’s website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.

For more information, please visit .

CONTACTS:

Jack A. Khattar, President and CEO

Timothy C. Dec, Senior Vice President and CFO

Supernus Pharmaceuticals, Inc.

(301) 838-2591

or

INVESTOR CONTACT:

Peter Vozzo

ICR Healthcare

(443) 213-0505



EN
23/04/2025

Underlying

SUPNSupernus Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Supernus Pharmaceuticals Inc.

 PRESS RELEASE
Free
SUPN Supernus Pharma...

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relatio...

Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom management ROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer. The series, which launches its first episode on the All About ADHD YouTube channel in May for Mental Health Awarenes...

May 29, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Announces Paragraph IV ANDA Filings for Qelbree®

Supernus Announces Paragraph IV ANDA Filings for Qelbree® ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company received Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules, eq. 100, 150, and 200 mg base. Supernus is currently reviewing the details o...

May 28, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus to Participate in the 2025 Jefferies Global Healthcare Confer...

Supernus to Participate in the 2025 Jefferies Global Healthcare Conference ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:00 p.m. ET in New York City. Investors interested in arranging a meeting with...

May 28, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresent...

Busy Philipps Empowers Women with ADHD to Go from Feeling Misrepresented to Being ‘Ms. Represented’ in First-of-its-Kind Campaign with Supernus Pharmaceuticals Females with ADHD frequently present with inattentive symptoms, which can be more difficult to recognize than the hyperactive and impulsive symptoms more often seen in malesBoys are two times more likely to be diagnosed with ADHD than girls, leaving many girls and women undiagnosed and untreatedBusy is flipping the script for women with ADHD by sharing her own diagnosis and treatment journey with Qelbree® (viloxazine extended-release...

May 20, 2025 1 EN
 PRESS RELEASE
Free
SUPN Supernus Pharma...

Supernus Announces First Quarter 2025 Financial Results

Supernus Announces First Quarter 2025 Financial Results First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 26% compared to the first quarter of 2024.First quarter 2025 operating loss of $(10.3) million, compared to oper...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch